Cipla share price
NSE: CIPLABSE: 500087Pharmaceuticals & BiotechnologyLarge Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,330.90.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,08,093 Cr99th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 23 Jul 2026
- 32.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 3.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.97%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 23 Jul 2026
- 10.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 23 Jul 2026
- 11.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 13,23,90058.1% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 23 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹7,119 Crup 8.84%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹786 Crup 44.80%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 11.0%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 31 Oct | Dec 2024Filed 29 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 25 Jul | Sep 2025Filed 30 Oct | Dec 2025Filed 23 Jan | Mar 2026Filed 13 May | Jun 2026Filed 23 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 | 6,541 | 7,119 |
| Net profit | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 | 543 | 786 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 18.5% | 22.3% | 18.0% | 18.6% | 17.8% | 9.5% | 8.3% | 11.0% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical and related products, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 63% of 2,234 trading days over the last 10 years.
At or below today's level on 21% of 1,974 trading days since Nov 2018.
At or below today's level on 95% of 1,910 trading days since Feb 2019.
At or below today's level on 86% of 2,459 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −14.1% | −26.4% | +15.4% | 1.1% |
| 3 years | +11.8% | +11.4% | −0.6% | 1.0% |
| 5 years | +9.4% | +10.0% | −1.4% | 0.9% |
Mutual funds holding it
338 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 170 of the 212 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 5 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 114
- CutCut. Funds that held fewer shares than at the end of the month before.
- 98
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 117
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 7
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 1,99,02,429 | 2.47% | ₹2,678.9 Cr |
 Parag Parikh Flexi Cap FundPPFAS Mutual Fund | 1,43,51,629 | 1.33% | ₹1,931.7 Cr |
 SBI Nifty 50 ETFSBI Mutual Fund | 1,09,15,593 | 0.72% | ₹1,469.2 Cr |
 ICICI Prudential Value FundICICI Prudential Mutual Fund | 57,30,736 | 1.35% | ₹771.4 Cr |
| SBI ELSS Tax Saver FundSBI Mutual Fund | 47,56,637 | 2.13% | ₹640.2 Cr |
| HDFC Focused FundHDFC Mutual Fund | 47,33,207 | 2.40% | ₹637.1 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 40,95,054 | 6.01% | ₹551.2 Cr |
| Nippon India Large Cap FundNippon India Mutual Fund | 40,86,211 | 1.07% | ₹550.0 Cr |
| SBI Contra FundSBI Mutual Fund | 38,36,985 | 1.15% | ₹516.5 Cr |
| ICICI Prudential Large Cap FundICICI Prudential Mutual Fund | 37,54,082 | 0.66% | ₹505.3 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Cipla in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical IndustriesSUNPHARMA | 4,19,404 | 34.7 | 5.0 | 23.1 | +11.4% | +16.6% | 15.5% | 16.9% | 0.92% |
 Divi's LaboratoriesDIVISLAB | 2,37,594 | 81.2 | 14.2 | 59.0 | +16.3% | +26.8% | 18.4% | 20.8% | 0.34% |
 Torrent PharmaceuticalsTORNTPHARM | 1,72,094 | 78.9 | – | – | +32.9% | +8.9% | 27.3% | 11.4% | 0.84% |
 Zydus LifesciencesZYDUSLIFE | 1,12,658 | 25.0 | 4.2 | 14.8 | +21.1% | −1.3% | 17.7% | 15.9% | 0.09% |
 Laurus LabsLAURUSLABS | 1,06,442 | 97.4 | 20.1 | 53.5 | +22.6% | +114.9% | 22.4% | 19.8% | 0.10% |
 Dr. Reddy's LaboratoriesDRREDDY | 1,02,624 | 31.8 | 2.7 | 20.5 | −0.9% | −43.3% | 9.0% | 6.8% | 0.65% |
 Mankind PharmaMANKIND | 91,390 | 44.6 | 5.6 | 25.4 | +13.8% | +8.2% | 13.4% | 12.8% | 0.00% |
 Aurobindo PharmaAUROPHARMA | 90,432 | 24.4 | 2.4 | 12.5 | +9.1% | +9.5% | 10.5% | 11.5% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 5 Jun 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹13.00 |
| 27 Jun 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹13.00 |
| 27 Jun 2025 | Special | ₹3.00 |
| 2 Aug 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹13.00 |
| 21 Jul 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹8.50 |
| 8 Aug 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹5.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
13 Oct · Analysts
Sep 2026
24 Sep · Disclosure
22 Sep · Management
Cipla share price by year
Each calendar year to 2025.Cipla share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,511.30 | −1.2% | 1,663.60 | 1,384.70 |
| 2024 | 1,529.00 | +22.7% | 1,680.50 | 1,251.00 |
| 2023 | 1,246.30 | +15.8% | 1,271.50 | 862.35 |
| 2022 | 1,075.95 | +14.0% | 1,173.40 | 867.45 |
| 2021 | 944.10 | +15.1% | 987.60 | 755.15 |
| 2020 | 819.95 | +71.5% | 833.20 | 374.70 |
| 2019 | 478.20 | −7.9% | 578.70 | 408.25 |
| 2018 | 519.50 | −14.6% | 672.80 | 512.55 |
| 2017 | 608.50 | +7.0% | 654.80 | 488.90 |
| 2016 | 568.80 | −12.5% | 655.35 | 464.90 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,332.40 | 1,338.00 | 1,314.10 | 1,338.00 | 1,325.50 | 13,23,900 | 58.1% |
| 22 Oct 2026 | 1,302.00 | 1,330.90 | 1,296.40 | 1,330.90 | 1,319.11 | 6,38,943 | 54.1% |
| 21 Oct 2026 | 1,324.10 | 1,337.50 | 1,308.30 | 1,314.00 | 1,314.43 | 12,38,869 | 68.1% |
| 19 Oct 2026 | 1,322.00 | 1,339.00 | 1,321.60 | 1,324.10 | 1,327.89 | 13,87,215 | 68.6% |
| 16 Oct 2026 | 1,335.00 | 1,337.50 | 1,315.10 | 1,325.10 | 1,324.45 | 8,50,284 | 62.5% |
| 15 Oct 2026 | 1,311.60 | 1,336.40 | 1,310.60 | 1,328.00 | 1,327.20 | 13,71,747 | 64.8% |
| 14 Oct 2026 | 1,333.30 | 1,333.30 | 1,302.70 | 1,314.60 | 1,311.28 | 9,94,166 | 67.3% |
| 13 Oct 2026 | 1,315.00 | 1,329.60 | 1,303.00 | 1,329.60 | 1,323.19 | 4,78,066 | 44.1% |
| 12 Oct 2026 | 1,307.40 | 1,317.40 | 1,300.20 | 1,311.30 | 1,311.12 | 6,66,122 | 66.9% |
| 9 Oct 2026 | 1,310.50 | 1,316.40 | 1,295.30 | 1,301.00 | 1,306.78 | 6,53,621 | 58.4% |
About Cipla
Cipla Limited is a pharmaceutical company that makes medicines for patients and serves 69 markets. Its range covers more than 1,500 products in over 50 dosage forms, including tablets, capsules, inhalers, nasal sprays, injections and oral liquids. It also produces active pharmaceutical ingredients, the active substances in medicines. The main therapeutic areas are respiratory, anti-retroviral, urology, cardiology, anti-infectives and central nervous system medicines.
Its key markets are grouped as One India, North America, One Africa, and Emerging Markets and Europe. One India covers branded prescription medicines, trade generics and consumer health. One Africa covers South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access. Its home markets are India, South Africa and North America.
Cipla operates 48 manufacturing facilities in five countries. In India these include sites at Kurkumbh, Patalganga, Bommasandra, Goa and Sikkim. It also manufactures in the United States, at Fall River in Massachusetts and on Long Island, as well as in South Africa and China. It has more than 31,000 permanent employees and workers across 18 countries.
Dr K A Hamied founded Cipla in August 1935. In 2001 it introduced a triple anti-retroviral therapy for HIV/AIDS in Africa at less than a dollar a day. It has also made acquisitions, including the Galvus brand in the year to March 2026 and Inzpera, which extends its presence in paediatrics and wellness. It develops biosimilars through a joint venture with Kemwell. Its registered office is in Lower Parel, Mumbai.
- Legal name
- Cipla Limited
- NSE symbol
- CIPLA
- BSE code
- 500087
- ISIN
- INE059A01026
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jul 1983 on BSE, Feb 1995 on NSE
- Face value
- ₹2
- CIN
- L24239MH1935PLC002380
- Corporate identity number, the registrar of companies' code for it